Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History

Journal of Substance Abuse Treatment

Volumn 57, Issue , 2015, Pages 75-80

  Clark, Robin E ^a   Baxter, Jeffrey D ^a   Aweh, Gideon ^a   O'Connell, Elizabeth ^a   Fisher, William H ^b   Barton, Bruce A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

Buprenorphine; Cost; Economic evaluation; Length of treatment; Medicaid; Methadone; Opioid addiction; Opioid agonists; Public policy; Substance abuse treatment; Treatment history

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; COMORBIDITY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; OPIATE ADDICTION; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SCHIZOPHRENIA; ECONOMICS; MULTIMODALITY CANCER THERAPY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANALGESICS, OPIOID; BEHAVIOR THERAPY; BUPRENORPHINE; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAID; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RECURRENCE; RISK FACTORS; UNITED STATES;

EID: 84940590478     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.05.001     Document Type: Article

References (21)

1. Baxter J.D., Clark R.E., Samnaliev M., Leung G.Y., Hashemi L. Factors associated with Medicaid patients' access to buprenorphine treatment. Journal of Substance Abuse Treatment 2011, 41(1):88-96.
2. Cacciola J.S., Dugosh K.L., Camilleri A.C. Treatment history: Relationship to treatment outcomes. Substance Use & Misuse 2009, 44:305-321.
3. Clark R.E., Baxter J.D. Responses of state medicaid programs to buprenorphine diversion: Doing more harm than good?. JAMA Internal Medicine 2013, 173(17):1571-1572.
4. Clark R.E., Samnaliev M., Baxter J.D., Leung G.Y. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs (Millwood) 2011, 30(8):1425-1433.
5. Clark R.E., Samnaliev M., McGovern M.P. Impact of substance disorders on medical expenditures for medicaid beneficiaries with behavioral health disorders. Psychiatric Services 2009, 60(1):35-42.
6. Cohen D.J., Crabtree B.F., Etz R.S., Balasubramanian B.A., Donahue K.E., Leviton L.C., et al. Fidelity versus flexibility: Translating evidence-based research into practice. American Journal of Preventive Medicine 2008, 35(5S):S381-S389.
7. Dennis M.L., Scott C.K., Funk R., Foss M.A. The duration and correlates of addiction and treatment careers. Journal of Substance Abuse Treatment 2005, 28(2):S51-S62.
8. Grella C.E., Hser Y.I., Joshi V., Anglin M.D. Patient histories, retention, and outcome models for younger and older adults in DATOS. Drug and Alcohol Dependence 1999, 57:151-166.
9. Heyman G.M. Addiction: A disorder of choice 2009, Harvard University Press, Cambridge, Massachusetts.
10. Hser Y.I., Grella C.E., Hsieh S.C., Anglin M.D., Brown B.S. Prior treatment experience related to process and outcomes in DATOS. Drug & Alcohol Dependence 1999, 57:137-150.
11. Hubbard R.L., Craddock S.G., Anderson J. Overview of 5-year followup outcomes in the Drug Abuse Treatment Outcome Studies (DATOS). Journal of Substance Abuse Treatment 2003, 25(3):125-134.
12. Kaiser Commission on Medicaid, the Uninsured Medicaid: A primer (issue brief) 2013, Kaiser Family Foundation.
13. Kronick R., Gilmer T., Dreyfus T., Lee L. Improving health-based payment for Medicaid beneficiaries: CDPS (Chronic Illness and Disability Payment System). Health Care Financing Review 2000, 21(3):29-64.
14. Mark T.L., Levit K.R., Yee T., Chow C.W. Spending on mental health and substance use disorders projected to grow more slowly than all health spending through 2020. Health Affairs 2014, 33:1407-1415.
15. Mattick R.P., Breen C., Kimber J., Davoli M. Buprenorphinemaintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, (2). CD002207. http://dx.doi.org/10.1002/14651858.CD002207.pub4.
16. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association 2000, 284(13):1689-1695.
17. Parthasarathy S., Weisner C., Hu T.W., Moore C. Association of outpatient alcohol and drug treatment with health care utilization and cost: Revisiting the offset hypothesis. Journal of Studies on Alcohol 2001, 62(1):89-97.
18. Rinaldo S.G., Rinaldo D.W. Advancing access to addiction medications. availability without accessibility? State Medicaid coverage and authorization requirements for opioid dependence medications (no. 1). American Society of Addiction Medicine 2013, 1-53. (online).
19. SAS Institute Inc. SAS version 8 1999, SAS Institute Inc., Cary, NC.
20. Simpson D.D., Joe G.W. A longitudinal evaluation of treatment engagement and recovery stages. Journal of Substance Abuse Treatment 2004, 27(2):89-97.
21. Volkow N.D., Friedan T.R., Hyde P.S., Cha S.S. Medication-assisted therapies-Tackling the opioid overdose epidemic. New England Journal of Medicine 2014, 370:2063-2066.